Zanubrutinib: adverse event reports filed with FDA

523

reports as suspect product

0% of all reports · about 69 a year

153

reports, 12 months to June 2026

91 in the 12 months before

95.4%

marked serious by the reporter

70.8% across the class

19.3%

record death among outcomes, as reported

101 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Zanubrutinib reports recording the termmedian drug in kinase inhibitor

1. Disease progressionthe disease advanced14.7%77
2. Anaemialow red blood cells11.7%61
3. Pneumonialung infection9.8%51
4. Thrombocytopenialow platelets9.6%50
5. Myelosuppression8%42
6. Off label useused for a purpose or in a way not on the label8%42
7. Covid-19COVID-19 infection7.8%41
8. Neutropenialow neutrophils, a type of white blood cell7.5%39
9. Drug ineffectivethe medicine did not work as expected6.7%35
10. White blood cell count decreasedlow white cell count6.3%33
11. Neutrophil count decreased6.1%32
12. Infectionan infection, type not specified5.9%31
13. Platelet count decreasedlow platelet count5.9%31
14. Atrial fibrillationan irregular heart rhythm5%26
15. Diarrhoealoose or frequent stools5%26
16. Pyrexiafever4.6%24
17. Deaththe patient died; cause not stated by this term4.4%23
18. Fatiguetiredness4.2%22
19. Rashskin rash4.2%22
20. Alanine aminotransferase increasedraised liver enzyme (ALT)4%21
21. Febrile neutropeniafever with low white blood cells4%21
22. Hypokalaemialow blood potassium4%21
23. Leukopenialow white blood cells4%21
24. Lymphocyte count decreased4%21
25. Aspartate aminotransferase increasedraised liver enzyme (AST)3.4%18
26. Haemorrhagebleeding3.4%18
27. Malignant neoplasm progression3.4%18
28. Nauseafeeling sick3.4%18
29. Lymphadenopathyswollen lymph nodes3.3%17
30. Hypertensionhigh blood pressure3.1%16

Top 30 of 225 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 100 drugs in the kinase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 849,161 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 18.5% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 523 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the kinase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zanubrutinib as a suspect or interacting product; reports listing it only as a concomitant medication (320) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.